Summary
Many drugs are known or suspected of having substantial first-pass hepatic metabolism in humans, and have low oral bioavailability on this basis. Hepatic disease might alter (increase) bioavailability by either or both of 2 mechanisms: decreased hepatic extraction due to impaired hepatic drug metabolising activity, or portosystemic shunting. Few studies have examined the effect of liver diseases on bioavailability, and even fewer have attempted to directly measure hepatic extraction of drugs in liver disease. Data are conflicting, with some evidence to suggest that hepalocyte function is preserved in moderate cirrhosis, while other evidence suggests a decrease in hepatic metabolic function. Several studies show relative preservation of systemic clearance in the face of substantial increases in bioavailability, suggesting that the hepatic arterial blood supply of the liver is an important determinant of systemic clearance in cirrhotic patients.
Increases in bioavailability and decreases in systemic clearance have multiplicative, rather than additive, effects on area under the plasma concentration-time curve after oral administration. Clinically, there are important implications of these studies. If differences in response between patients with and without liver disease are seen after equivalent intravenous doses of a high clearance drug, the differences may be further accentuated after oral dosing. Delayed toxicity, due to accumulation of high clearance drugs is more likely to occur because of the longer half-life and larger available dose. Physicians should use extra caution in administering high clearance compounds to patients with liver disease.
Similar content being viewed by others
References
Alvan, G.; Lind, M.; Meilstrom, B. and von Bahr, C.: Importance of ‘first-pass elimination’ for interindividual differences in steady-state concentrations of the adrenergic β-receptor antagonist alprenolol. Journal of Pharmacokinetics and Biopharmaceutics 5: 193–205 (1977).
Amman, R. and Olsson, R.: Elimination of paracetamol in chronic liver disease. Acta Hepato-Gastroenterologica 25: 283–286 (1978).
Barr, W.H.; Aceto, T.; Chung, M. and Shukur, M.: Dose dependent drug metabolism during the absorptive phase. Reviews of Canadian Biology 32 (Suppl.): 31–42 (1973).
Benowitz, N.L. and Meister, W.: Pharmacokinetics in patients with heart failure. Clin. Pharmacokin. 1: 389–405 (1976).
Blaschke, T.F.: Protein binding and kinetics of drugs in liver disease. Clinical Pharmacokinetics 2: 32 (1977).
Branch, R.A. and Shand, D.G.: Propranolol disposition in chronic liver disease: a physiological approach. Clinical Pharmacokinetics 1: 264–279 (1976).
Branch, R.A.; Kornhauser, D.M.; Shand, D.G.; Wilkinson, G.R. and Wood, A.J.J.: Biological determinants of Propranolol disposition in normal subjects and patients with cirrhosis. British Journal of Clinical Pharmacology 4: 630P (1977).
Branch, R.A.; Shand, D.G.; Wilkinson, G.R. and Nies, A.S.: Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. Journal of Clinical Investigation 53: 1101–1107 (1974).
Christophidis, N.; Vajda, F.J.E.; Lucas, I.; Drummer, O.; Moon, W.J. and Louis, W.J.: Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clinical Pharmacokinetics 3: 330–335 (1978).
Du Souich, P.; McLean, A.J.; Lalka, D.; Erill, S. and Gibaldi, M.: Pulmonary disease and drug kinetics. Clinical Pharmacokinetics 3: 257–266 (1978).
Esquivel, M.; Blaschke, T.F.; Snidow, G.H. and Meffin, P.J.: Effect of phenobarbitone on the disposition of lidocaine and warfarin in the dog. Journal of Pharmacy and Pharmacology 30: 804–805 (1978).
Gibaldi, M. and Perrier, D.: Route of administration and drug disposition. Drug Metabolism Reviews 3: 185–199 (1974).
Gomeni, R.; Bianchetti, G.; Sega, R. and Morselli, P.L.: Pharmacokinetics of Propranolol in normal healthy volunteers. Journal of Pharmacokinetics and Biopharmaceutics 5: 183–192 (1977).
Groszman, R.; Kotelanski, B.; Cohn, J.N. and Khati, I.M.: Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. American Journal of Medicine 53: 715–722 (1972).
Gugler, R.; Lain, P. and Azarnoff, D.L.: Effects of portocaval shunt on the disposition of drugs with and without first pass effect. Journal of Pharmacology and Experimental Therapeutics 195: 416–423 (1975).
Hepnew, G.W.: Breath tests in gastroenterology. Advances in Internal Medicine 23: 25–45 (1978).
Homeida, M.; Jackson, L. and Roberts, C.J.C.: Decreased first pass metabolism of labetalol in chronic liver disease. British Medical Journal 2: 1048–1050 (1978).
Jaillon, P.; Rubin, P.; Yee, G.; Ball, R.; Kates, R.; Harrison, D. and Blaschke, T.: The influence of congestive heart failure on Prazosin pharmacokinetics. Clinical Pharmacology and Therapeutics 25: 790–794 (1979).
Jostell, K.G.; Agurell, S.; Hollister, L.E. and Wermuth, B.: Kinetics of chlormethiazole in patients with alcohol withdrawal manifestations. Clinical Pharmacology and Therapeutics 23: 181–187 (1978).
Laut, W.W.: The hepatic artery: subservient to hepatic metabolism or guardian of normal hepatic clearance rates of humoral substances. General Pharmacology 8: 73–78 (1977).
Lavene, D.; Weiss, Y.A.; Safar, M.E.; Loria, Y.; Agorus, N.; Georges, D. and Milliez, P.L.: Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function. Journal of Clinical Pharmacology 17: 501–508 (1977).
Neal, E.A.; Meffin, P.J.; Gregory, P.B. and Blaschke, T.F.: Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 77: 96–102 (1979).
Nies, A.S.; Shand, D.G. and Wilkinson, G.R.: Altered hepatic blood flow and drug disposition. Clinical Pharmacokinetics 1: 135–155 (1976).
Paterson, J.W.; Dollery, C.T.; Conolly, M.E.; Hayes, A. and Cooper, R.G.: Pharmacodynamics and metabolism of Propranolol in man. European Journal of Clinical Pharmacology 2: 217 (1970).
Pentikainen, P.J.; Neuvonen, P.J.; Tarpida, S. and Syvalakti, E.: Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole. British Medical Journal 2: 861–863 (1978).
Pessayre, D.; Lebrec, D.; Descatoire, V.; Peignoud, M. and Benhemou, J.P.: Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology 74: 566–571 (1978).
Reidenberg, M.: Kidney disease and drug metabolism. Medical Clinics of North America 58: 1059–1062 (1974).
Routledge, P.A. and Shand, D.A.: Clinical pharmacokinetics of Propranolol. Clinical Pharmacokinetics 4: 73–90 (1979).
Rowland, M.: Effect of some physiological factors on bioavailability of oral dosage forms; in Swarbrick (Ed) Current Concepts in Pharmaceutical Science: Biopharmaceutics, pp.181–230 (M. Dekker, Inc., New York 1973).
Rowland, M.; Blaschke, T.F.; Meffin, P.J. and Williams, R.L.: Pharmacokinetics in disease states modifying hepatic and metabolic function; in Benet (Ed) The Effect of Disease States on Drug Pharmacokinetics (American Pharmaceutical Association, Washington 1976).
Shand, D.G. and Rangno, R.E.: The disposition of Propranolol. Pharmacology 7: 159–168 (1972).
Talseth, T.: Clinical pharmacokinetics of hydrallazine. Clinical Pharmacokinetics 2: 317–329 (1977).
Tschang, C.; Steiner, J.A.; Hignite, C.E.; Huffman, D.H. and Azarnoff, D.L.: Systemic availability of lidocaine in patients with liver disease (Abstract). Clinical Research 25: 609A (1977).
Wood, A.J.J.; Kornhauser, D.M.; Wilkinson, G.R.; Shand, D.G. and Branch, R.A.: The influence of cirrhosis on steady-state blood concentrations of unbound Propranolol after oral administration. Clinical Pharmacokinetics 3: 478–487 (1978).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blaschke, T.F., Rubin, P.C. Hepatic First-pass Metabolism in Liver Disease. Clin Pharmacokinet 4, 423–432 (1979). https://doi.org/10.2165/00003088-197904060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-197904060-00002